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OBJECTIVE:
 
 The Minimum Data Set (MDS) is an inter-
national facility-reported database used to standardize
the assessment process and improve the quality of care in
nursing homes. Specific MDS assessments are used as
quality indicators to determine the prevalence of antipsy-
chotic prescribing as well as potentially inappropriate anti-
psychotic usage. MDS classifies low-risk residents as receiv-
ing an antipsychotic medication but having no documented
psychotic or related condition and no cognitive impairment
with behavioral symptoms. Without an audit of resident
records, it is impossible to determine if the MDS accurately
reports the prevalence of antipsychotic medications and
whether all low-risk residents represent inappropriate
prescribing. The purpose of this study was to deter-
mine MDS validity for identifying low-risk residents in
Texas.
METHODS: Facility-based MDS assessments were com-
pared to independent on-site assessments. A team of
pharmacists reviewed the chart records of low risk resi-
dents and determined whether a resident received an an-
tipsychotic medication and the presence or absence of a
valid indication. These findings were compared to the
statewide MDS quality indicator prevalence rate.
RESULTS: Based on MDS assessments, 10,163 residents
from 1021 nursing homes were identified as low risk.
The chart records revealed that 12.4% of these residents
were not receiving antipsychotic medication. Of the 8904
residents who were receiving an antipsychotic, 48.2%
had a valid diagnosis or indication and were mistakenly
identified as low-risk by the MDS database. Of the re-
maining 4610 residents, 84.4% were missing a diagnosis
and 15.6% had an inappropriate indication.
CONCLUSION: For this population of residents, a lack
of accurate essential diagnostic information in MDS as-
sessments and a high prevalence of inappropriate antipsy-
chotic prescribing was found to be a widespread prob-
lem. These findings indicate that nursing facilities were
inaccurate in their responses to MDS assessment items
and therefore, the MDS had poor validity as a quality in-
dicator for antipsychotic use.
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OBJECTIVE:
 
 Practice guidelines are being implemented
for many diseases to improve outcomes, increase use of
evidence-based medicine, and to reduce medical errors.
Rarely are these efforts systematically evaluated in clini-
cal care. We chose breast cancer in women as one disease
that has excellent scientific evidence on treatment efficacy
but almost no data on actual use in physician practice.
METHODS: We studied use of breast conserving sur-
gery, breast reconstruction, adjuvant chemotherapy, radi-
ation, taxoids, tamoxifen, and aromatase inhibitors in el-
igible women. The population was diagnosed between
1995 and 2000 in six surgical oncology practices in the
eight counties around Philadelphia with nearly seven mil-
lion people. Four thousand three hundred ninety five
women were enrolled and followed retrospectively up to
five years after diagnosis. We abstracted each patient’s
complete clinical record.
RESULTS: Lumpectomy was provided to 51.0% of
women, among whom 2.3% also had reconstruction.
Forty nine percent of women (49.0%) had mastectomy
with 18.0% having breast reconstruction, 56.8% re-
ceived radiation therapy and 32.3% received adjuvant
chemotherapy. Among eligible women, 0.6% had aro-
matase inhibitors and 12.3% were prescribed taxoids.
Among estrogen and/or progesterone-receptor-positive
women, 72.4% got tamoxifen, while 35.1% with nega-
tive estrogen and progesterone receptors got tamoxifen.
One woman refused all treatment, one refused any breast
surgery, five refused adjuvant chemotherapy, two refused
radiation. Eight percent of eligible women refused tamox-
ifen, mainly because of elevated risk of adverse side effects,
and one had an autologous bone marrow transplant. Lo-
gistic regression found that breast reconstruction was in-
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versely related to patient age (p 
 

 
 .0029), tamoxifen var-
ied directly with patient age (p 
 

 
 .0002) but inversely
with physician age (p  .02), and adjuvant chemotherapy
and taxoids varied inversely with patient age (p  .0001).
CONCLUSIONS: Two decades of multiple randomized
control trials and meta-analyses have led to only modest
success in the use of highly beneficial treatments for
breast cancer in these specific oncology practices, al-
though non-beneficial treatments are almost never used.
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OBJECTIVE:
 
 To evaluate the factors influencing the utiliza-
tion of prescribed medications across the United States.
 
METHODS:
 
 Prescription claims data for a random sam-
ple of commercially insured Express Scripts members, 18
to 64 years of age and continuously eligible for at least
two months in 1999 (N  1,467,699), were geo-coded at
the block group level. Key independent variables included
age, gender, family size, median income, education, ur-
ban/rural location, client type, and pharmacy benefit de-
sign. Outcome measures included any use of prescrip-
tions. Hierarchical modeling (HLM) was used to control
for clustering of patients within health plans.
RESULTS: Results from HLM indicate that after control-
ling for demographics, client type, and pharmacy benefit
design, variation in the probability of using a prescribed
medication was found across regions of the country.
Members in the South have a greater likelihood of use
and members in the Northeast and West having a lower
probability of use than members in the Midwest. A
greater probability of use was associated with older age,
female gender, higher income, family size 1, and enroll-
ment in a managed care plan. Factors associated with
lower probability of prescription use included presence of
a deductible, living in an urban area and having a manda-
tory generic policy.
CONCLUSIONS: While patient age and gender remain
key factors driving prescription utilization, socioeconom-
ics, pharmacy benefit design, and where a person lives are
also predictors of prescription use. Future research is
needed to better understand the causative roles of disease
burden, physician practice style, and consumer preferences
in prescription drug use variation across the United States.
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OBJECTIVE:
 
 The objective of this study was to derive a
brief, clinically relevant symptom index for men with
HRPCa.
 
METHODS:
 
 An international sample of 44 medical on-
cologists, radiation oncologists, and urologists were pre-
sented with 29 disease-related symptoms derived from
the Functional Assessment of Cancer Therapy-Prostate
(FACT-P) quality of life (QOL) instrument and asked to
select the five most important symptoms in assessing the
treatment response for men with HRPCa. Symptoms en-
dorsed at a frequency greater than chance were retained
for the index. Retrospective validation of the index was
accomplished using data from a multi-national, random-
ized, double-blind, placebo-controlled clinical trial of
atrasentan, a selective, oral ET-A receptor antagonist.
The FACT-P and European Organization for Research
and Treatment of Cancer (EORTC) QLQ-C30 adminis-
tered at baseline, six weeks and final visit were used to
evaluate QOL responses to treatment of 288 men with
HRPCa.
RESULTS: Experts initially selected eight priority symp-
toms. Item-Response Theory analysis identified one mis-
fitting item (worry), lending support for a seven-item in-
dex (FPSI-7). Internal consistency was high for the seven-
item index (0.75). Concurrent validity was established
through correlations (P  0.05) between the FPSI-7 and
the FACT-General (FACT-G; r  0.56); FACT-P (r 
0.73); FACT Prostate Cancer Subscale (PCS; r  0.88);
Trial Outcome Index (TOI; r  0.83); and QLQ-C30
global score (r  .56), symptom domain scores (r 
0.33 to 0.76), and generic domain scores (r  0.36 to
0.60). The FPSI-7 successfully differentiated patients by
functional status, measured by the Eastern Cooperative
Oncology Group (ECOG) performance status rating
(PSR, p  .001), and clinical outcome, measured by dis-
ease progression status (p  .001). PSR and disease pro-
gression are important outcomes for patients and clinical
trials. The FPSI-7’s responsiveness to PSR change com-
pared favorably to the FACT-G, PCS, FACT-P and TOI.
CONCLUSION: The FPSI-7 is a valid and responsive
symptom index that can provide efficient, rapid symptom
assessment to evaluate treatment outcome in clinical trials.
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OBJECTIVES: To evaluate resource consumption related
to mucositis in lymphoma patients receiving high-dose
chemotherapy (HDC) with autologous PBPC transplan-
tation.
